-
In one of the more bizarre stories of the year, the FDA has uncovered files of counterfeit Procrit (epoetin alfaJohnson & Johnson) in routine surveillance. To make matters worse, the fake vials have been contaminated with bacteria and many contain no active ingredient.
-
-
There are no well-defined guidelines for the treatment of primary cutaneous B-cell lymphoma (PCBCL). Since it is an uncommon diagnosis, it is unlikely that answers will come from randomized trials. This retrospective study from 2 German centers evaluated outcomes from a cohort of 35 patients and concluded that radiotherapy to all visible lesions is the treatment of choice.
-
Women with advanced epithelial ovarian cancer did not describe the treatment decision-making process as shared; rather, they described an interaction that was directed by their physician.
-
Participants in the initial Multicenter Study of Hydroxyurea in Sickle Cell Anemia interventional trial were followed, upon completion of that trial for up to 9 years, to determine the long-term effects of treatment. In this publication of the observational phase of the MSH trial, there is noted a 40% reduction in mortality for those who had received a year or more of the drug.
-
-
In a trial that included androgen-independent prostate cancer patients, 2 drug regimens were shown by randomized phase II analysis to be comparable. Both produced survival advantage when compared to prior series, including those in which mitoxantrone and prednisone were used.
-
In this series, the only prognostic factor for patients with advanced-stage borderline tumor is the type of peritoneal implant. More patients died of the treatments complications than of the disease itself.
-
Docetaxel is active in paclitaxel-resistant ovarian and peritoneal cancer, but, in view of significant hematologic toxicity, further study is warranted to ascertain its optimal dose and schedule.
-
